Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 11, November, p. 1549–1554

doi: 10.17219/acem/74178

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Homocysteine level in patients with obstructive sleep apnea/hypopnea syndrome and the impact of continuous positive airway pressure treatment

Jie Li1,A,B,C,F, Li-Qiang Yu1,A,B,C,F, Min Jiang2,B,C,D,F, Ling Wang1,A,D,F, Qi Fang3,B,C,E,F

1 Department of Special Requirements, 1st Affiliated Hospital of Soochow University, Suzhou, China

2 Clinical Laboratory, 1st Affiliated Hospital of Soochow University, Suzhou, China

3 Department of Neurology, 1st Affiliated Hospital of Soochow University, Suzhou, China

Abstract

Background. Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a common disorder in the general population.
Objectives. The aim of this study was to investigate the homocysteine (Hcy) level in the patients with OSAHS of varying degrees and the effect of continuous positive airway pressure (CPAP) treatment on OSAHS patients.
Material and Methods. A total of 117 OSAHS patients were recruited and divided into 3 groups (mild OSAHS, moderate OSAHS and severe OSAHS), while 33 non-OSAHS people were selected as control group. For all cases, polysomnography (PSG) variables and the concentrations of Hcy, methane dicarboxylic aldehyde (MDA) and glutathione (GSH) were recorded. Serum Hcy was measured by cyclophorase. The values of MDA and GSH were measured by a spectrophotometer. In the severe OSAHS group, a total of 30 patients received CPAP for more than 4 h every night and were re-examined 6 months later.
Results. The serum levels of Hcy, MDA and GSH showed a significant difference in OSAHS patients and controls. The Hcy and GSH concentrations of OSAHS patients with CPAP treatment showed no apparent change compared with the prior treatment, but the MDA level was obviously lower after CPAP treatment. In controls and the mild/moderate OSAHS groups, multi-element linear regression analysis results indicated that there was a statistically significant relationship between the Hcy concentration and various independent variables (age, MDA, GSH, and the apnea-hypopnea index – AHI).
Conclusion. The change of the Hcy level was not proportional to the severity of the disease in different groups of OSAHS patients, and CPAP did not affect the Hcy levels.

Key words

continuous positive airway pressure, obstructive sleep apnea/hypopnea syndrome, homocysteine

References (30)

  1. Jennum P, Riha RL. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur Respir J. 2009;33(4):907–914.
  2. Destors M, Tamisier R, Baguet JP, Levy P, Pepin JL. Cardiovascular morbidity associated with obstructive sleep apnea syndrome [in French]. Rev Mal Respir. 2014;31(4):375–385.
  3. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: An American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). J Am Coll Cardiol. 2008;52(8):686–717.
  4. Lombardi C, Musicco E, Bettoncelli G, et al. The perception of obstructive sleep apnoea/hypopnoea syndrome (OSAHS) among Italian general practitioners. Clin Mol Allergy. 2015;13(1):1–7.
  5. McDaid C, Durée KH, Griffin SC, et al. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep Med Rev. 2009;13(6):427–436.
  6. Murri M, Alcazar-Ramirez J, Garrido-Sanchez L, et al. Oxidative stress and metabolic changes after continuous positive airway pressure treatment according to previous metabolic disorders in sleep apnea-hypopnea syndrome patients. Transl Res. 2009;154(3):111–121.
  7. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest. 2008;134(4):686–692.
  8. Hernández C, Abreu J, Abreu P, Colino R, Jiménez A. Effects of nasal positive airway pressure treatment on oxidative stress in patients with sleep apnea-hypopnea syndrome. Arch Bronconeumol. 2006;42(3):125–129.
  9. Djuric D, Jakovljevic V, Rasic-Markovic A, Djuric A, Stanojlovic O. Homocysteine, folic acid and coronary artery disease: Possible impact on prognosis and therapy. Indian J Chest Dis Allied Sci. 2008;50(1):39–48.
  10. Niu X, Chen X, Xiao Y, et al. The differences in homocysteine level between obstructive sleep apnea patients and controls: A meta-analysis. PLoS One. 2014;9(4):e95794.
  11. Wang L, Jie LI, Xie Y, Zhang XG. Association between serum homocysteine and oxidative stress in elderly patients with obstructive sleep apnea/hypopnea syndrome. Biomed Environ Sci. 2010;23(1):42–47.
  12. Toshiaki S, Taniguchi AA, Ryujiro S, et al. Falling asleep while driving and automobile accidents among patients with obstructive sleep apnea-hypopnea syndrome. Psychiatry Clin Neurosci. 2002;56(3):333–334.
  13. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol. 2003;91(10): 1265–1269.
  14. Sariman N, Levent E, Aksungar FB, Soylu AC, Bektaş O. Homocysteine levels and echocardiographic findings in obstructive sleep apnea syndrome. Respiration. 2009;79(1):38–45.
  15. Thakre TP, Mamtani M, Ujaoney S, Kulkarni H. Association of plasma homocysteine with self-reported sleep apnea is confounded by age: Results from the National Health and Nutrition Examination Survey 2005–2006. J Strategic Inf Syst. 2015;16(4):324–352.
  16. Niu X, Chen X, Xiao Y, et al. The differences in homocysteine level between obstructive sleep apnea patients and controls: A meta-analysis. PLoS One. 2013;9(4):e95794.
  17. Monneret D, Tamisier R, Ducros V, et al. The impact of obstructive sleep apnea on homocysteine and carotid remodeling in metabolic syndrome. Respir Physiol Neurobiol. 2012;180(2–3):298–304.
  18. Cintra F, Tufik S, D’Almeida V, et al. Cysteine: A potential biomarker for obstructive sleep apnea. Chest. 2011;139(2):246–252.
  19. Sacco RL, Anand K, Lee HS, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: The Northern Manhattan Study. Stroke. 2004;35(10):2263–2269.
  20. Wang L, Li J, Xie Y, Zhang XG. Association between serum homocysteine and oxidative stress in elderly patients with obstructive sleep apnea/hypopnea syndrome. Biomed Environ Sci. 2010;23(1): 42–47.
  21. Sánchez-Armengol A, Villalobos-López P, Caballero-Eraso C, et al. Gamma glutamyl transferase and oxidative stress in obstructive sleep apnea: A study in 1744 patients. Sleep Breath. 2015;19(3):1–8.
  22. Alvarez RF, Cuadrado GR, Arias RA, et al. Snoring as a determinant factor of oxidative stress in the airway of patients with obstructive sleep apnea. Lung. 2016;194(3):1–5.
  23. Ntalapascha M, Makris D, Kyparos A, et al. Oxidative stress in patients with obstructive sleep apnea syndrome. Sleep Breath. 2013;17(2):549–555.
  24. Sardo L, Palange P, Di Mario F, et al. Intrarenal hemodynamic and oxidative stress in patients with obstructive sleep apnea syndrome. Sleep Breath. 2015;19(4):1205–1212.
  25. Mancuso M, Bonanni E, Logerfo A, et al. Oxidative stress biomarkers in patients with untreated obstructive sleep apnea syndrome. Sleep Med. 2012;13(6):632–636.
  26. Sato K, Umeno H, Chitose S, Nakashima T. Sleep-related deglutition in patients with OSAHS under CPAP therapy. Acta Otolaryngol. 2011; 131(2):181–189.
  27. Guo J, Sun Y, Xue LJ, et al. Effect of CPAP therapy on cardiovascular events and mortality in patients with obstructive sleep apnea: A meta-analysis. Sleep Breath. 2016;20(3):1–10.
  28. Chen X, Niu X, Xiao Y, et al. Effect of continuous positive airway pressure on homocysteine levels in patients with obstructive sleep apnea: A meta-analysis. Sleep Breath. 2014;18(4):687–694.
  29. Kumor M, Bielicki P, Przybyłowski T, Rubinsztajn R, Zieliński J, Chazan R. Three-month continuous positive airway pressure (CPAP) therapy decreases serum total and LDL cholesterol, but not homocysteine and leptin concentration in patients with obstructive sleep apnea syndrome (OSAS) [in Polish]. Pneumonol Alergol Pol. 2011;79(3):173–183.
  30. Tichanon P, Wilaiwan K, Sopida S, Orapin P, Watchara B, Banjamas I. Effect of continuous positive airway pressure on airway inflammation and oxidative stress in patients with obstructive sleep apnea. Can Respir J. 2016;2016(4):1–7.
© Wroclaw Medical University